NewAmsterdam Pharma Co N.V. (NAMS) stock
NAMSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NAMSW
$19.39−0.07 (-0.36%)
Close on Nov 17, 2026Market cap $2.32BP/E –Yield –
NewAmsterdam Pharma cash
Cash and short-term investments held at the end of each period.
NewAmsterdam Pharma's cash was $633.85M at Jun 30, 2026. For fiscal 2025 it was $636.24M, down 23.7% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $636.24M | -23.7% |
| FY2024 | Dec 31, 2024 | $834.19M | +145.0% |
| FY2023 | Dec 31, 2023 | $340.45M | -27.2% |
| FY2022 | Dec 31, 2022 | $467.73M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $633.85M | -14.2% |
| Q1 FY2026 | Mar 31, 2026 | $636.11M | -21.3% |
| Q4 FY2025 | Dec 31, 2025 | $636.24M | -23.7% |
| Q3 FY2025 | Sep 30, 2025 | $702.95M | +66.3% |
| Q2 FY2025 | Jun 30, 2025 | $739.16M | +71.6% |
| Q1 FY2025 | Mar 31, 2025 | $808.48M | +68.0% |
| Q4 FY2024 | Dec 31, 2024 | $834.19M | +145.0% |
| Q3 FY2024 | Sep 30, 2024 | $422.73M | -9.6% |
| Q2 FY2024 | Jun 30, 2024 | $430.71M | – |
| Q1 FY2024 | Mar 31, 2024 | $481.15M | – |
| Q4 FY2023 | Dec 31, 2023 | $340.45M | – |
| Q4 FY2022 | Dec 31, 2022 | $467.73M | – |
See a number that looks wrong?